Consensus Considerations and Good Practice Points for Use of Continuous Glucose Monitoring Systems in Hospital Settings

Julie L V Shaw; Raveendhara R Bannuru; Lori Beach; Nuha A ElSayed; Guido Freckmann; Anna K Füzéry; Angela W S Fung; Jeremy Gilbert; Yun Huang; Nichole Korpi-Steiner; Samantha Logan; Rebecca Longo; Dylan MacKay; Lisa Maks; Stefan Pleus; Kendall Rogers; Jane Jeffrie Seley; Zachary Taxin; Fiona Thompson-Hutchison; Nicole V Tolan; Nam K Tran; Guillermo E Umpierrez; Allison A Venner

doi:10.2337/dci24-0073

Consensus Considerations and Good Practice Points for Use of Continuous Glucose Monitoring Systems in Hospital Settings

Diabetes Care. 2024 Dec 1;47(12):2062-2075. doi: 10.2337/dci24-0073.

Authors

Julie L V Shaw¹, Raveendhara R Bannuru², Lori Beach³, Nuha A ElSayed^{2

4}, Guido Freckmann⁵, Anna K Füzéry^{6

7}, Angela W S Fung⁸, Jeremy Gilbert⁹, Yun Huang¹⁰, Nichole Korpi-Steiner¹¹, Samantha Logan^{6

12}, Rebecca Longo¹³, Dylan MacKay¹⁴, Lisa Maks¹⁵, Stefan Pleus⁵, Kendall Rogers¹⁶, Jane Jeffrie Seley¹⁷, Zachary Taxin¹⁸, Fiona Thompson-Hutchison¹⁹, Nicole V Tolan²⁰, Nam K Tran²¹, Guillermo E Umpierrez²², Allison A Venner^{6

12}

Affiliations

¹ Division of Biochemistry, Eastern Ontario Regional Laboratory Association and The Ottawa Hospital, and Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, Canada.
² American Diabetes Association, Arlington, VA.
³ Division of Biochemistry, IWK Health, Department of Pathology and Laboratory Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
⁴ Harvard Medical School, Cambridge, MA.
⁵ Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany.
⁶ Alberta Precision Laboratories, Edmonton, Alberta, Canada.
⁷ Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
⁸ Department of Pathology and Laboratory Medicine, St. Paul's Hospital, Providence Health Care and University of British Columbia, Vancouver, British Columbia, Canada.
⁹ Division of Endocrinology and Metabolism, Sunnybrook Health Sciences Centre, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
¹⁰ Division of Biochemistry, Kingston Health Sciences Centre, and Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
¹¹ Department of Pathology and Laboratory Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
¹² Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
¹³ Lahey Hospital & Medical Center, Burlington, MA.
¹⁴ Departments of Food and Human Nutritional Sciences and Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
¹⁵ Providence Health Care, Vancouver, British Columbia, Canada.
¹⁶ Division of Hospital Medicine, Department of Internal Medicine, The University of New Mexico School of Medicine, Albuquerque, NM.
¹⁷ Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, New York, NY.
¹⁸ Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
¹⁹ Integrated Community Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
²⁰ Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
²¹ Department of Pathology and Laboratory Medicine, UC Davis Health, University of California, Davis, Sacramento, CA.
²² Division of Endocrinology and Metabolism, Department of Medicine, Emory School of Medicine, Emory University, Atlanta, GA.

PMID: 39452893
DOI: 10.2337/dci24-0073

Abstract

Continuous glucose monitoring (CGM) systems provide frequent glucose measurements in interstitial fluid and have been used widely in ambulatory settings for diabetes management. During the coronavirus disease 2019 (COVID-19) pandemic, regulators in the U.S. and Canada temporarily allowed for CGM systems to be used in hospitals with the aim of reducing health care professional COVID-19 exposure and limiting use of personal protective equipment. As such, studies on hospital CGM system use have been possible. With improved sensor accuracy, there is increased interest in CGM usage for diabetes management in hospitals. Laboratorians and health care professionals must determine how to integrate CGM usage into practice. The aim of this consensus guidance document is to provide an update on the application of CGM systems in hospital, with insights and opinions from laboratory medicine, endocrinology, and nursing.

Publication types

Review

MeSH terms

Blood Glucose Self-Monitoring / instrumentation
Blood Glucose Self-Monitoring / methods
Blood Glucose* / analysis
COVID-19* / epidemiology
Consensus*
Continuous Glucose Monitoring
Coronavirus Infections / epidemiology
Diabetes Mellitus / blood
Hospitals
Humans
Pandemics*
Pneumonia, Viral / epidemiology
SARS-CoV-2

Substances

Blood Glucose

Abstract

Publication types

MeSH terms

Substances

Grants and funding